X
Tuesday, July 15, 2025
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Sterling Pharma Solutions commence the production of potential COVID-19 treatment

Content Team by Content Team
12th May 2020
in Manufacturing, Press Statements
Sterling Pharma Solutions commence the production of potential COVID-19 treatment

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has commenced production of hydroxychloroquine (HCQ), a treatment currently under investigation for COVID-19.

Sterling will be manufacturing the active pharmaceutical ingredient (API) with the finished product being manufactured and supplied by Accord Healthcare.

The UK’s current supply of HCQ is sourced from overseas, primarily as a result of economic pressures driving production to lower cost manufacturing regions. This new deal with Accord will establish a domestic supply of the product ensuring access for patients in the UK, should the drug prove successful.

Kevin Cook CEO at Sterling Pharma Solutions said, “While it is currently unclear whether HCQ will be a viable treatment for COVID-19, it is vital to proactively establish a strong supply route ahead of time.

“Rapid response to a rapidly changing landscape has been key here. We have worked quickly alongside Accord Healthcare to establish a UK supply chain for this product.

“HCQ could potentially provide an effective treatment for COVID patients and during such an unprecedented time it’s important that the pharmaceutical industry works flexibly to achieve maximum results as quickly as possible and this partnership is a good example of that.”

Sterling has already supported Accord with the purchase of over 50 tonnes of the key raw materials, which equates to roughly 60 million finished tablets of HCQ.

As a result of the partnership Accord expects to supply up to 50 million HCQ tablets per month and has already started production of HCQ from its manufacturing facility in Barnstable, UK.

About Sterling Pharma Solutions

Sterling Pharma Solutions is a global contract development and manufacturing organisation with world-class facilities in the UK and US. Combining a full-service offering with expert knowledge and technical agility to offer API development and cGMP contract manufacturing capabilities the team can support projects through the entire product lifecycle from grams to tonnes.

With over 50 years’ experience of delivering first-class service to the pharmaceutical industry the exceptionally talented team combine their unrivalled knowledge and skillset with first-class customer service to ensure high quality project delivery, every time.

Previous Post

CoVIg-19 Plasma Alliance: International Organizations Work on Globulin Therapy for COVID-19

Next Post

Thermo Fisher Scientific Announces SARS-CoV-2 GlobalAccess Sequencing Program

Related Posts

Pharma Advancement Banner
Press Statements

Welcome to the Inaugural Operationalize: Expanded Access Programs Summit West

27th June 2025
Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
Regulatory Trends in Pharma
Insights

Regulatory Trends in Pharma Manufacturing to Watch in 2025

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Next Post
New Multi-Instrument Calibrator Designed to Improve Accuracy and Save Time for Leak Detection and Repair Compliance

Thermo Fisher Scientific Announces SARS-CoV-2 GlobalAccess Sequencing Program

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Notifications